RECRUITING

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Description

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.

Conditions

Recurrent or Metastatic Solid Tumors
Talk to us

Related Conditions:

Recurrent or Metastatic Solid Tumors

Study Overview

On this page

Study Details

Study overview

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colorectal cancer (CRC); hepatocellular carcinoma (HCC); adenocarcinoma of esophagus, gastroesophageal junction, and stomach (Ad-Eso/GEJ/gastric); urothelial carcinoma (UC); ovarian cancer (OVC); cervical cancer (CC); biliary tract cancer (BTC); human epidermal growth factor 2 (HER2)-low breast cancer (BC); HER2 immunohistochemistry (IHC) 0 BC; and cutaneous melanoma.

A Phase 1B/2 Pan-Tumor, Open-Label Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

Condition
Recurrent or Metastatic Solid Tumors
Intervention / Treatment

-

Contacts and Locations

Los Angeles

Los Angeles Cancer Network, Los Angeles, California, United States, 90017

Los Angeles

Valkyrie Clinical Trials, Los Angeles, California, United States, 90067

Whittier

Pih Health Hematology Medical Oncology, Whittier, California, United States, 90602

Skokie

Orchard Healthcare Research Inc., Skokie, Illinois, United States, 60077

Minneapolis

Regents of the University of Minnesota, Minneapolis, Minnesota, United States, 55455

New York

New York University Medical Center Prime, New York, New York, United States, 10016

New York

Icahn School of Medicine At Mount Sinai Prime, New York, New York, United States, 10029

Westbury

Clinical Research Alliance, Westbury, New York, United States, 11590

Chattanooga

Tn Gynecologic Oncology Group, Llc, Chattanooga, Tennessee, United States, 37403

Germantown

The West Clinic, Germantown, Tennessee, United States, 38138

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

    Ages Eligible for Study

    18 Years to

    Sexes Eligible for Study

    ALL

    Accepts Healthy Volunteers

    No

    Collaborators and Investigators

    Daiichi Sankyo,

    Study Record Dates

    2028-07-25